arrow
M

Michail Ignatiadis

institut jules bordet
H指数:54
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Risk stratification and potential overtreatment in adjuvant CDK4/6 inhibitor trials: do all patients with Stage II disease and favorable biology derive benefit?

辅助CDK4/6抑制剂试验中的风险分层和潜在过度治疗:所有具有II期疾病和良好生物学特征的患者都能获益吗?

2026-10-310
PRE
Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2− breast cancer: a randomized phase 2 trial

durvalumab和oleclumab新辅助立体定向放射治疗ER HER2 − 乳腺癌: 一项随机2期试验

2026-06-250
OAAI
Corrigendum to “International expert consensus on the clinical integration of circulating tumor cells in solid tumors” [Eur. J. Cancer 231 (2025) 116050]

勘误:“International expert consensus on the clinical integration of circulating tumor cells in solid tumors” [Eur. J. Cancer 231 (2025) 116050]

2025-12-100
PRE
Personalized ctDNA detection and genomic profiling in the NeoRHEA Study

个性化循环肿瘤DNA检测和基因组分析在NeoRHEA研究中

2025-12-050
OAAI
Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: The NeoRHEA phase 2 study

Palbociclib和内分泌疗法减弱早期乳腺癌的适应性抗肿瘤免疫:NeoRHEA 2期研究

2025-11-260
OAAI
Development of a Machine Learning Model for Predicting Treatment-Related Amenorrhea in Young Women with Breast Cancer

开发一种用于预测年轻乳腺癌女性治疗相关性闭经的机器学习模型

2025-10-290
OAAI
International expert consensus on the clinical integration of circulating tumor cells in solid tumors

实体瘤中循环肿瘤细胞临床整合的国际专家共识

2025-10-200
PRE
Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial
2025-05-010
PRE
Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications
2024-11-260
OAAI
EORTC-2129-BCG: Elacestrant for treating ER+/HER2-breast cancer patients with ctDNA relapse (TREAT ctDNA)

EORTC-2129-BCG: Elacestrant用于治疗ER+/HER2-乳腺癌伴有ctDNA复发的患者(TREAT ctDNA)

2024-09-011
PRE
Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study Editoral Comment
2024-08-010
OA
Genomic and intrinsic subtype correlates of serum thymidine kinase activity in patients with metastatic breast cancer treated with palbociclib and fulvestrant in the PYTHIA trial
2024-05-020
PRE
RBsig geneexpression signature in patients with endocrine resistant metastatic breast cancer treated with palbociclib and fulvestrant in the PYTHIA trial
2024-05-020
PRE
Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial
2024-05-023
PRE
Pregnancy after breast cancer in young women with germline BRCA pathogenic variants: results from an international cohort study
2024-05-020
PRE